Related Experiment Video
Updated: Sep 17, 2025
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Unveiling the silent threat: COVID-19 and myocardial injury
1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.
Insights
COVID-19 can cause significant myocardial injury, affecting 30-50% of patients and leading to death. This review highlights the importance of recognizing and treating cardiac complications from COVID-19 and vaccines.
Area of Science:
- Cardiology
- Infectious Diseases
- Immunology
Background:
- COVID-19, initially known for respiratory symptoms, increasingly shows cardiac involvement.
- Myocardial injury affects 30-50% of COVID-19 patients, a significant cause of mortality, even without severe lung disease.
- Post-vaccination myocarditis is a growing global concern, characterized by severe inflammation and potential fatality.
Purpose of the Study:
- To raise awareness of myocardial injury associated with COVID-19.
- To provide evidence and experience for managing cardiac complications from COVID-19 and vaccines.
- To review pathogenesis, clinical features, diagnosis, and treatment of COVID-19-related myocardial injury.
Main Methods:
- Comprehensive literature review of studies on COVID-19 and myocardial injury.
- Analysis of research on pathogenesis, clinical symptoms, diagnosis, and treatment.
- Emphasis on the role of Renin-Angiotensin System (RAS) inhibitors, particularly Angiotensin II Receptor Blockers (ARBs).
Main Results:
- Myocardial injury is a prevalent and serious complication of COVID-19.
- Cardiac involvement can be a primary cause of death in COVID-19 patients.
- Myocardial injury and myocarditis are detectable and treatable conditions.
Conclusions:
- Myocardial injury is a critical aspect of COVID-19 and its long-term effects.
- Early detection and management are crucial for patients with cardiac complications from COVID-19 or vaccines.
- RAS inhibitors, especially ARBs, play a vital role in managing myocardial injury.
Abstract:
Since COVID-19 firstly appeared in 2019 December, it has been defined as an infectious disease mainly performing lung symptoms, which contracted more attention. However, more and more findings indicate myocardial injury appears in considerable proportion of COVID-19 patients (30 % - 50 %) not only but also major cause leading to the death in patients, many of whom may be even without severe respiratory symptoms. Meanwhile myocarditis after injecting vaccines has been paid more attention to globally which always performs uncontrollable inflammation and lead to death. Now myocardial injury has been a main complication in patients with long COVID-19, which is worthy of attention. Furthermore, myocardial injury or myocarditis is detectable and treatable. In order to abstract attention to myocardial injury associated with COVID-19 and provide more evidence and experience for patients who still suffer myocardial injury from COVID-19 vaccines or long COVID-19, the review comprehensively summarized previous researches from pathogenesis, clinical symptoms, diagnosis and treatment and emphasized the crucial role of RASS inhibitors especially ARBs.
Related Concept Videos
01:14Myocarditis III: Medical Management
01:21Myocarditis I: Introduction
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:22Myocarditis IV: Nursing Management
01:30Acute Coronary Syndrome I: Introduction
01:28Acute Coronary Syndrome IV: Interprofessional Care